Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECOMMEND: Neoadjuvant Chemotherapy Cycles in Gastric Cancer
NCT03413514Unknown
- Sponsor
- Peking University
- Start
- Jan 2018
- Primary completion
- Jan 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Open-label, single-arm trial of tegafur and oxaliplatin in gastric cancer (GC), sponsored by Peking University. Primary endpoint: The cycle of neoadjuvant chemotherapy at 18 months. Status: unknown.
02
Drugs
tegafuroxaliplatin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT03413514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03413514.